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Abstract
To examine the relationship between mitochondrial DNA (mtDNA) alterations and colorectal
tumorigenesis, we used high-resolution restriction endonucleases and sequencing to assess the
mitochondrial genome from three histologic subtypes of colorectal adenomas (tubular = 8;
tubulovillous = 9; and villous = 8), colorectal cancer (CRC) tissues = 27, and their matched
surrounding normal tissue (MSNT) = 52. The mitochondrial genomes were amplified using 9 pairs
of overlapping primers and systematically analyzed by means of high-resolution analysis. DNA
fragments showing a shift in banding patterns between the three adenomas, CRC, in comparison
to the MSNT were sequenced to identify the mtDNA alterations. A total of thirty-eight germ-line
mtDNA variants were observed in this study. Twenty-two of the thirty-eight were identified as
mutations and 59% (13 of 22) were silent mutations and one was a 1-bp insertion. Sixteen of thirty-
eight were distinct SNPs in flanking regions of the restriction sites and, 6 of the 16 (37%) SNPs were
not previously reported. Most of these mutations/SNPs were homoplasmic and distributed in
various regions of mitochondrial genes including the 16S and 12S rRNA. Based on our results,
mtDNA germline variants increased in prevalence with adenoma CRC progression. To the best of
our knowledge, this is the first report to show an increased prevalence of mitochondrial gene
variants in CRC tumorigenesis.
Findings
Colorectal polyps are a frequent occurrence in the general
population and adenomatous changes in these polyps are
associated with the overwhelming majority of CRC. These
adenomas are the precursor lesions of colon cancer [1].
Currently, clinical management of individuals with color-
ectal polyps is guided by the histology of the lesion [2].
However, the accuracy of an appropriate staging of color-
ectal polyps progression to cancer continues to confound
clinical pathologists as well as surgeons. Alternative strat-
egies, which augment pathological findings such as the
identification of molecular markers that are associated
with the colorectal tumor progression, may prove to be a
useful as a prognostic tool and a preoperative stage-spe-
cific evaluation. Recently, there have been reports of the
potential use of mtDNA mutations as a biomarker in the
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solid tumor of other cancers [3-6] due its repaired less effi-
ciently compared with that of nuclear DNA. Also, Mito-
chondria have been implicated in cancer given their role
in apoptosis [7,8] and its vulnerability to mutation due to
the close proximity to a major source of reactive oxygen
species (ROS). Nevertheless, definitive mtDNA mutations
associated with the progression of tumors such as CRC
have yet to be established. Given the connection between
mitochondria, ROS, and neoplasia, mtDNA from CRC
adenoma, cancer tissues, and pathologically determined
matched surrounding non-cancerous tissue were screened
for variants, which may be used as biomarkers for colorec-
tal cancer progression. We speculated that there is an asso-
ciation between one or more mtDNA mutations in the
adenomatous polyps and CRC progression and the cumu-
lative frequencies of such mtDNA mutations may eventu-
ally be demonstrated to be an important marker in
adenoma colorectal progression.
This study was approved by the Institutional Review
Board of Morehouse School of Medicine and the Research
Oversite Committee of the Grady Memorial Hospital,
Atlanta, Georgia and the University of Alabama at Bir-
mingham School of Medicine, Birmingham, Alabama.
Primary fresh frozen and paraffin embedded tissues from
3 histologic subtypes of adenomatous polyps (8 tubular;
9 tubulovillous; and 8 villous), 27 CRC tissues, and histo-
logically MSNT, n = 52 were obtained from the Tissue Pro-
curement Network at the University of Alabama at
Birmingham and the Department of Surgery of More-
house School of Medicine/Grady Hospital. Adenomas
were defined by histologic type, degree of dysplasia, and
presence of infiltrating adenocarcinoma in adenoma and
classified as tubular, tubulovillus, and villous. CRC diag-
nosis was confirmed by histological examinations of bios-
pied specimens for all patients and pathological tumor
staging for these was based on American Joint Committee
on Cancer [9]. The mean age of the study subjects was
66.3 ± 5.7 years.
Genomic DNA was extracted from both frozen and paraf-
fin embedded remnant tissues using Tri-Reagent (Molecu-
lar, Research Center Inc., Cincinnati, Ohio) and Purgene
DNA purification kits (Gentra Systems, Minneapolis,
Minnesota) according to the manufacture's protocol. The
mtDNA from each tissue sample was amplified by PCR
using nine overlapping mtDNA primer pairs as previously
described [10,11], which resulted in large PCR products
that exclude the possibility that nuclear pseudogenes were
amplified. Each PCR product was digested with 14 restric-
tion endonucleases (AluI, AvaII, BamHI, Dde I, HaeII,
HaeIII, HhaI, HincII, HinfI, HpaI, MspI, MboI, RsaI, and
TaqI) and then subjected to direct sequencing of both
sense and anti-sense strands with ABI 3100 Genetic Ana-
lyzer to determine the exact nature of new length poly-
morphisms/mutations detected by restriction analysis.
Sequences were compared (BLAST) to the human mito-
chondrial DNA sequence (Genbank Accession #J01415).
The MITODAT database was used to identify mitochon-
drial genome sequence variants.
The analysis of mtDNA samples by restriction digestion
and sequencing of the DNA fragments showed non-pre-
dicted banding patterns either as homoplasmic single
bandshifts or heteroplasmic multiple bands on the gel.
The PCR product data point in overlapping regions were
counted only once. However overlapping regions were
used as internal controls for the identification of the vari-
ants. Results of the high-resolution restriction analyses
and sequencing of the entire mitochondrial genome
yielded 38 sequence variants (including 16 SNPs from the
flanking restriction sites) for the precursor adenomatous
polyps and cancer tissues. In no instance was a variant
detected in the adenomatous tissue found in the histolog-
ically matched adjacent surrounding tissue, indicating
that these were germ-line origin.
Based upon our assessment of the mitochondrial DNA
from non-cancer, precancerous (adenomatous polyps),
and colorectal cancer tissues using a high-resolution
restriction analysis, we have identified sequence variants.
To our knowledge this is the first assessment of the mito-
chondrial genome using solely primary tissue rather than
cell lines. This is important since tissues in culture can
undergo clonal evolution which can distort frequency
data. Although, the restriction analyses identified a
number of band shifts indicating site gains or losses, these
data only indicated that the predicted sequence had
changed. They did not identify specific base pair changes.
We therefore used the original primers and a series of
nested primers to sequence the band shifts in order to
identify these specific changes. A total of thirty-eight
germ-line mtDNA variants were observed and all muta-
tions/SNPs were considered as germ-line origin since the
variants found in the colorectal adenoma polyps or can-
cerous tissues were also found in the MSNT tissues.
Twenty-two of the thirty-eight were identified as muta-
tions and 59% (13 of 22) were mostly silent mutations of
T-to-C. or a G-to-A transition, which is consistent with the
mutagenic spectra of oxidative, damage [12,13]. Among
them, C3316T/A (ND1; Met-to Met/Ile), G2758A
(16SrRNA), T2352C (16SrRNA), A4769G (ND2; Met-to-
Met), A3759G (ND1;CUN), G5178T (ND2; CUN-to-Met)
G7028A (COI; Ala-to-Ala) T7055C/G (COI; Gly-to-Gly)
C7498T (S(UCN)), G6260A (COI; Glu-to-Gly), G8251A
(COII; Gly-to-Gly) T8784C (ATPase 6; Gly-to-Gly)
A8618G (ATPase6; Ile-to-Thr), G9055A (ATPase 6, Ala-to-
Thr), A8860G (ATPase 6 Thr-to-Ala), T11641C (ND4;
Met-to-Met), A10398G (ND3; Thr-to-Ala), C10400T
(ND3; Thr-to-Ala), C12633A(ND5;S(UCN)),Molecular Cancer 2004, 3:30 http://www.molecular-cancer.com/content/3/1/30
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C16390T(D-loop), T16519C(tRNAVal). However, one was
a 9-bp Ins5892C in a non-coding region between MTTY
and MTCOI. Some of these mutations are located in ATP
synthase genes that are involved in mtDNA genome main-
tenance and integrity in yeast [14]. Seventy-five percent
(39 of 52) of a G8860A (Thr-to-Ala) mutation in ATPase
6 gene was detected among CRC adenomas and cancer tis-
sues, compared to 14% (7 of 52) in MSNT tissues. This
mutational spectrum in ATPase gene could lead to a less
efficient mtDNA replication and abnormalities as previ-
ously suggested by Maximo et al. [15]. Sixteen of thirty-
eight were distinct SNPs in flanking regions of the restric-
tion sites and 10 of the 16 (63%) have been reported, and
6 were not recorded in the MITODAT database [#J01415].
The identified SNPs are 3107delG (ND1; Frameshift),
T2914G (16SrRNA), A2706G (16SrRNA), A2768G
(16SrRNA), T2885C (16SrRNA), C7521T (tRNAAsp),
7335insC (COI; Frameshift), G7256A (COI; Asn-to-Asn),
T7146A (COI; Thr-to-S(UCN)), G8206A (COI; Met-to-
Met), A16325G (D-loop), T16309G (D-loop), G16294A
(D-loop), G16266A (D-loop), G16233A (D-loop), 8269-
9bp del (noncoding). Worth mentioning is also the high
frequency of 16S rRNA gene variants (> 65%) in the
mtDNA among CRC tissue versus the < 25% in the pre-
cancerous tissues. Mutations in the 16S rRNA gene were
commonly found in different cancers, except those of the
thyroid [16].
We then sought to determine whether or not any of
mtDNA variants observed in flanking regions of these
restriction site variants may prove to be informative
biomarkers. Although, a total of 38 of the mtDNA variants
were found, none of the variants appeared to be a marker
for a particular adenoma CRC tumor tissue type. Never-
Frequencies of mitochondrial genome variants based on high-restriction analysis in all of the colorectal tumors (tubular, tubu- lovillous, villous), cancer tissues in each of the 9 primer sets Figure 1
Frequencies of mitochondrial genome variants based on high-restriction analysis in all of the colorectal tumors (tubular, tubu-
lovillous, villous), cancer tissues in each of the 9 primer sets. Numbers on the abscissa represent PCR products obtained using 
overlapping primers sets 1–9, termed haploblocks (Rank methods; for all comparsion).
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theless, cumulative frequencies of mtDNA variants in the
different tissue types resulted in a high prevalence of
mtDNA sequence variants in CRC tissue and the trend was
for the number of variants to be lowest in the precancer-
ous (Fig. 1), suggesting that this may be a useful approach
to distinguishing the progressive stages of CRC adenomas
as previously observed in tumour progression in the thy-
roid [17]. Our sample of CRC adenomas is relatively small
and these data must not be overinterpreted at this point.
The data however are suggestive and the cumulative fre-
quency approach is currently being followed-up. It is pos-
sible that the high frequency of variants in mtDNA in CRC
cancer tissues may result from the high rate of mtDNA
replication. Furthermore, most of the mtDNA mutations
in this study could be a result of mtDNA aggression
affected by reactive oxygen species [18-21] and could
occur via a slipped replication mechanism [22].
These data should be interpreted cautiously as they are
based on small number of sample size. Similar studies
have looked at precancerous tissue types [20], however
they have not assessed cumulative frequencies of muta-
tions in these same tissues as we have done. Our study is
also different in that we did not use cell lines for this work.
Moreover, consistent with our findings were reports of
cumulative mitochondrial DNA damage in the aging
process as well as in cancer [23]. A similar mechanism
may be involved in colorectal cancer progression, since
age is a risk factor for CRC.
Abbreviations
MtDNA, mitochondrial DNA; ATP, adenosine triphos-
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